Cargando…

Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction

SIMPLE SUMMARY: Cancer is a complex, heterogeneous collection of diseases with hundred of different subtypes. Genomic aberrations that are primarily thought to be the root causes of different cancers have been clinically used as evidence for both the diagnosis and also matching individual patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Baranovskii, Artem, Gündüz, Irem B., Franke, Vedran, Uyar, Bora, Akalin, Altuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688044/
https://www.ncbi.nlm.nih.gov/pubmed/36428696
http://dx.doi.org/10.3390/cancers14225604
_version_ 1784836167162658816
author Baranovskii, Artem
Gündüz, Irem B.
Franke, Vedran
Uyar, Bora
Akalin, Altuna
author_facet Baranovskii, Artem
Gündüz, Irem B.
Franke, Vedran
Uyar, Bora
Akalin, Altuna
author_sort Baranovskii, Artem
collection PubMed
description SIMPLE SUMMARY: Cancer is a complex, heterogeneous collection of diseases with hundred of different subtypes. Genomic aberrations that are primarily thought to be the root causes of different cancers have been clinically used as evidence for both the diagnosis and also matching individual patients to proper treatment options. However, the complexity of cancer manifests itself differently in each patient when inspected at the molecular level. Even patients with the same cancer type rarely have identical root causes for the same disease. Without an extensive molecular profile of a patient, it has been challenging to match the patients to the best treatment options. To remedy this, comprehensive genomic profiling panels have been developed to monitor hundreds of genes for a given patient, which has helped broaden the treatment options for patients. However, genomic aberrations detected in such panels still do not reflect the full complexity of how a tumour responds to cancer drugs. In this study, we demonstrate that using an additional layer of molecular information (called the transcriptome) on top of genomic aberrations that can be detected with cancer gene panels can provide significant improvements in predicting the cancer drug response in pre-clinical cancer models. Thus, this study serves as a push towards incorporating the transcriptome measurements more routinely in (pre-)clinical practice. ABSTRACT: Comprehensive genomic profiling using cancer gene panels has been shown to improve treatment options for a variety of cancer types. However, genomic aberrations detected via such gene panels do not necessarily serve as strong predictors of drug sensitivity. In this study, using pharmacogenomics datasets of cell lines, patient-derived xenografts, and ex vivo treated fresh tumor specimens, we demonstrate that utilizing the transcriptome on top of gene panel features substantially improves drug response prediction performance in cancer.
format Online
Article
Text
id pubmed-9688044
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96880442022-11-25 Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction Baranovskii, Artem Gündüz, Irem B. Franke, Vedran Uyar, Bora Akalin, Altuna Cancers (Basel) Communication SIMPLE SUMMARY: Cancer is a complex, heterogeneous collection of diseases with hundred of different subtypes. Genomic aberrations that are primarily thought to be the root causes of different cancers have been clinically used as evidence for both the diagnosis and also matching individual patients to proper treatment options. However, the complexity of cancer manifests itself differently in each patient when inspected at the molecular level. Even patients with the same cancer type rarely have identical root causes for the same disease. Without an extensive molecular profile of a patient, it has been challenging to match the patients to the best treatment options. To remedy this, comprehensive genomic profiling panels have been developed to monitor hundreds of genes for a given patient, which has helped broaden the treatment options for patients. However, genomic aberrations detected in such panels still do not reflect the full complexity of how a tumour responds to cancer drugs. In this study, we demonstrate that using an additional layer of molecular information (called the transcriptome) on top of genomic aberrations that can be detected with cancer gene panels can provide significant improvements in predicting the cancer drug response in pre-clinical cancer models. Thus, this study serves as a push towards incorporating the transcriptome measurements more routinely in (pre-)clinical practice. ABSTRACT: Comprehensive genomic profiling using cancer gene panels has been shown to improve treatment options for a variety of cancer types. However, genomic aberrations detected via such gene panels do not necessarily serve as strong predictors of drug sensitivity. In this study, using pharmacogenomics datasets of cell lines, patient-derived xenografts, and ex vivo treated fresh tumor specimens, we demonstrate that utilizing the transcriptome on top of gene panel features substantially improves drug response prediction performance in cancer. MDPI 2022-11-15 /pmc/articles/PMC9688044/ /pubmed/36428696 http://dx.doi.org/10.3390/cancers14225604 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Baranovskii, Artem
Gündüz, Irem B.
Franke, Vedran
Uyar, Bora
Akalin, Altuna
Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
title Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
title_full Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
title_fullStr Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
title_full_unstemmed Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
title_short Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
title_sort multi-omics alleviates the limitations of panel sequencing for cancer drug response prediction
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688044/
https://www.ncbi.nlm.nih.gov/pubmed/36428696
http://dx.doi.org/10.3390/cancers14225604
work_keys_str_mv AT baranovskiiartem multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction
AT gunduziremb multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction
AT frankevedran multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction
AT uyarbora multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction
AT akalinaltuna multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction